Logo

Agilent Completes Seahorse Bio Acquisition

Nov 02, 2015 | staff reporter

NEW YORK (GenomeWeb) – Agilent Technologies today announced the completion of its acquisition of Seahorse Bioscience.

Agilent said in a statement that Seahorse's technology for measuring cell metabolism and bioenergetics complements Agilent's separations and mass spectrometry business. The approximately 200 Seahorse employees are now a part of the Mass Spectrometry Division of the Life Sciences and Applied Markets Group.

Agilent did not disclose the final purchase price; however, it announced a definitive agreement to buy Billerica, Massachusetts-based Seahorse in September, for $235 million in cash.

Filed under

Business News
Proteomics & Protein Research
asset acquisition
metabolomics
Agilent
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.